Treatment considerations in patients with concomitant viral infection and autoimmune rheumatic diseases

Best Practice and Research: Clinical Rheumatology

Volumn 29, Issue 2, 2015, Pages 319-342

  Louthrenoo, Worawit ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Anti TNF ; Arthritis; Autoimmune rheumatic diseases; Immunosuppressive drugs; Reactivation; Virus

Indexed keywords

ABATACEPT; ALPHA INTERFERON; ANTIRHEUMATIC AGENT; BIOLOGIC DISEASE MODIFYING ANTIRHEUMATIC DRUG; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOSUPPRESSIVE AGENT; LIVE VACCINE; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

AUTOIMMUNITY; CARCINOGENESIS; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; JC VIRUS; LYMPHOMA; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PATIENT MONITORING; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATIC DISEASE; SYSTEMATIC REVIEW (TOPIC); VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS REACTIVATION; WART VIRUS; COMPLICATION; DRUG EFFECTS; PATHOPHYSIOLOGY; RHEUMATIC DISEASES; VIRAL PHENOMENA AND FUNCTIONS; VIRUS ACTIVATION;

ANTIRHEUMATIC AGENTS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RHEUMATIC DISEASES; VIRUS ACTIVATION; VIRUS DISEASES; VIRUS PHYSIOLOGICAL PHENOMENA;

EID: 84941180816     PISSN: 15216942     EISSN: 15321770     Source Type: Journal    
DOI: 10.1016/j.berh.2015.05.010     Document Type: Review

References (175)

1. S. Ramiro, C. Gaujoux-Viala, J.L. Nam, and et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis Ann Rheum Dis 73 2014 529 535
2. C. Trepo, H.L. Chan, and A. Lok Hepatitis B virus infection Lancet 384 2014 2053 2063
3. I. Merican, R. Guan, D. Amarapuka, and et al. Chronic hepatitis B virus infection in Asian countries J Gastroenterol Hepatol 15 2000 1356 1361
4. R. Watanabe, T. Ishii, H. Kobayashi, and et al. Prevalence of hepatitis B virus infection in patients with rheumatic diseases in tohoku area: a retrospective multicenter survey Tohoku J Exp Med 233 2014 129 133
5. M. Sui, R. Wu, X. Hu, and et al. Low prevalence of hepatitis B virus infection in patients with autoimmune diseases in a Chinese patient population J Viral Hepat 21 2014 925 929
6. C.J. Zou, L.J. Zhu, Y.H. Li, and et al. The association between hepatitis B virus infection and disease activity, synovitis, or joint destruction in rheumatoid arthritis Clin Rheumatol 32 2013 787 795
7. X. Liang, S. Bi, W. Yang, and et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination Vaccine 27 2009 6550 6557
8. J. Tan, J. Zhou, P. Zhao, and et al. Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs Clin Rheumatol 31 2012 1169 1175
9. B. Zheng, T. Li, Q. Lin, and et al. Prevalence of hepatitis B surface antigen in patients with ankylosing spondylitis and its association with HLA-B27: a retrospective study from south China Rheumatol Int 32 2012 2011 2016
10. M.H. Chen, L.T. Hsiao, M.H. Chen, and et al. Clinical significance of chronic hepatitis B virus infection in patients with primary Sjogren's syndrome Clin Rheumatol 31 2012 309 315
11. S. Mori Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/or nonbiological disease-modifying antirheumatic drugs Mod Rheumatol 21 2011 621 627
12. J. Zhao, M. Qiu, M. Li, and et al. Low prevalence of hepatitis B virus infection in patients with systemic lupus erythematosus in southern China Rheumatol Int 30 2010 1565 1570
13. M. Marcos, F. Alvarez, P. Brito-Zeron, and et al. Chronic hepatitis B virus infection in Sjogren's syndrome. Prevalence and clinical significance in 603 patients Autoimmun Rev 8 2009 616 620
14. X. Guennoc, V. Narbonne, S. Jousse-Joulin, and et al. Is screening for hepatitis B and hepatitis C useful in patients with recent-onset polyarthritis? the ESPOIR cohort study J Rheumatol 36 2009 1407 1413
15. H. Permin, J. Aldershvile, and J.O. Nielsen Hepatitis B virus infection in patients with rheumatic diseases Ann Rheum Dis 41 1982 479 482
16. J.H. Hoofnagle Reactivation of hepatitis B Hepatology 49 2009 S156 S165
17. W. Yeo, P.K. Chan, S. Zhong, and et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors J Med Virol 62 2000 299 307
18. N. Droz, L. Gilardin, P. Cacoub, and et al. Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases Arthritis Care Res Hob 65 2013 1504 1514
19. A. Kempinska, E.J. Kwak, and J.B. Angel Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B-immune patient: case report and review of the literature Clin Infect Dis 41 2005 1277 1282
20. S.J. Kim, C. Hsu, Y.Q. Song, and et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group Eur J Cancer 49 2013 3486 3496
21. J.M. Kim, H. Park, H.R. Jang, and et al. High pretransplant HBV level predicts HBV reactivation after kidney transplantation in HBV infected recipients Ann Surg Treat Res 86 2014 256 263
22. W. Yeo, P.K. Chan, P. Hui, and et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study J Med Virol 70 2003 553 561
23. W. Yeo, T.C. Chan, N.W. Leung, and et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab J Clin Oncol 27 2009 605 611
24. R. Tur-Kaspa, R.D. Burk, Y. Shaul, and et al. Hepatitis B virus DNA contains a glucocorticoid-responsive element Proc Natl Acad Sci U. S. A 83 1986 1627 1631
25. T.W. Kim, M.N. Kim, J.W. Kwon, and et al. Risk of hepatitis B virus reactivation in patients with asthma or chronic obstructive pulmonary disease treated with corticosteroids Respirology 15 2010 1092 1097
26. W. Du, Z. Zheng, S. Han, and et al. HBV reactivation in an occult HBV infection patient treated with prednisone for nephrotic syndrome: case report and literature review BMC Infect Dis 13 2013 394
27. J.H. Bae, J.H. Sohn, H.S. Lee, and et al. A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier Clin Mol Hepatol 18 2012 225 228
28. D. Xuan, Y. Yu, L. Shao, and et al. Hepatitis reactivation in patients with rheumatic diseases after immunosuppressive therapy-a report of long-term follow-up of serial cases and literature review Clin Rheumatol 33 2014 577 586
29. K.C. Tse, S. Yung, C. Tang, and et al. Management of hepatitis B reactivation in patients with lupus nephritis Rheumatol Int 29 2009 1273 1277
30. G.Y. Gwak, K.C. Koh, and H.Y. Kim Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate Clin Exp Rheumatol 25 2007 888 889
31. S. Ito, K. Nakazono, A. Murasawa, and et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient Arthritis Rheum 44 2001 339 342
32. M.B. Carroll, and M.I. Bond Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection Semin Arthritis Rheum 38 2008 208 217
33. H. Ye, X.W. Zhang, R. Mu, and et al. Anti-TNF therapy in patients with HBV infection-analysis of 87 patients with inflammatory arthritis Clin Rheumatol 33 2014 119 123
34. H.H. Ryu, E.Y. Lee, K. Shin, and et al. Hepatitis B virus reactivation in rheumatoid arthritis and ankylosing spondylitis patients treated with anti-TNFalpha agents: a retrospective analysis of 49 cases Clin Rheumatol 31 2012 931 936
35. J.L. Lan, Y.M. Chen, T.Y. Hsieh, and et al. Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy Ann Rheum Dis 70 2011 1719 1725
36. A. Tamori, T. Koike, H. Goto, and et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts J Gastroenterol 46 2011 556 564
37. R. Caporali, F. Bobbio-Pallavicini, F. Atzeni, and et al. Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases Arthritis Care Res Hob 62 2010 749 754
38. D. Vassilopoulos, A. Apostolopoulou, E. Hadziyannis, and et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection Ann Rheum Dis 69 2010 1352 1355
39. S.J. Chung, J.K. Kim, M.C. Park, and et al. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy J Rheumatol 36 2009 2416 2420
40. F. Cantini, S. Boccia, D. Goletti, and et al. HBV reactivation in patients treated with antitumor necrosis factor-alpha (TNF-alpha) agents for rheumatic and dermatologic conditions: a systematic review and meta-analysis Int J Rheumatol 2014 2014 926836
41. A. Pyrpasopoulou, S. Douma, T. Vassiliadis, and et al. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis Rheumatol Int 31 2011 403 404
42. S. Lovric, U. Erdbruegger, P. Kumpers, and et al. Rituximab as rescue therapy in anti-neutrophil cytoplasmic antibody-associated vasculitis: a single-centre experience with 15 patients Nephrol Dial Transpl 24 2009 179 185
43. I. Mitroulis, C. Hatzara, A. Kandili, and et al. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection Ann Rheum Dis 72 2013 308 310
44. A. Fanouriakis, D. Vassilopoulos, A. Repa, and et al. Hepatitis B reactivation following treatment with abatacept in a patient with past hepatitis B virus infection Rheumatol Oxf 53 2014 195 196
45. P.S. Kim, G.Y. Ho, P.E. Prete, and et al. Safety and efficacy of abatacept in eight rheumatoid arthritis patients with chronic hepatitis B Arthritis Care Res Hob 64 2012 1265 1268
46. T. Nagashima, and S. Minota Tocilizumab for rheumatoid arthritis with chronic hepatitis B virus infection without antiviral therapy J Rheumatol 37 2010 1066
47. H. Tsuboi, A. Tsujii, A. Nampei, and et al. A patient with rheumatoid arthritis treated with tocilizumab together with lamivudine prophylaxis after remission of infliximab-reactivated hepatitis B Mod Rheumatol 21 2011 701 705
48. D. Kishida, Y. Okuda, M. Onishi, and et al. Successful tocilizumab treatment in a patient with adult-onset Still's disease complicated by chronic active hepatitis B and amyloid A amyloidosis Mod Rheumatol 21 2011 215 218
49. K.G. Saag, G.G. Teng, N.M. Patkar, and et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 59 2008 762 784
50. D.E. Furst, E.C. Keystone, J. Braun, and et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011 Ann Rheum Dis 71 Suppl. 2 2012 i2-45
51. C. Charpin, S. Guis, P. Colson, and et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients Arthritis Res Ther 11 2009 R179
52. C.K. Hui, W.W. Cheung, H.Y. Zhang, and et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy Gastroenterology 131 2006 59 68
53. M. Harigai, S. Mochida, T. Mimura, and et al. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy Mod Rheumatol 24 2014 1 7
54. G.L. Armstrong, A. Wasley, E.P. Simard, and et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 144 2006 705 714
55. D.F. Cuadros, A.J. Branscum, F.D. Miller, and et al. Spatial epidemiology of hepatitis C virus infection in Egypt: analyses and implications Hepatology 60 2014 1150 1159
56. J. Chan Hepatitis C Dis Mon 60 2014 201 212
57. T. Ansemant, P. Ornetti, J.F. Garrot, and et al. Usefulness of routine hepatitis C and hepatitis B serology in the diagnosis of recent-onset arthritis. Systematic prospective screening in all patients seen by the rheumatologists of a defined area-brief report Jt Bone Spine 79 2012 268 270
58. A. El Garf, B. El Zorkany, R. Gheith, and et al. Prevalence and clinical presentations of hepatitis C virus among patients admitted to the rheumatology ward Rheumatol Int 32 2012 2691 2695
59. P. Mohan, M. Rajasekaran, P. Ramanathan, and et al. Prevalence of hepatitis C virus antibodies in systemic lupus erythematosus Eur J Gastroenterol Hepatol 21 2009 1437 1438
60. A. Ceribelli, I. Cavazzana, R. Cattaneo, and et al. Hepatitis C virus infection and primary Sjogren's syndrome: a clinical and serologic description of 9 patients Autoimmun Rev 8 2008 92 94
61. M.M. Ahmed, S.M. Berney, R.E. Wolf, and et al. Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus Am J Med Sci 331 2006 252 256
62. V.S. Barbosa, N.A. Silva, and R.M. Martins Hepatitis C virus seroprevalence and genotypes in patients with diffuse connective tissue diseases and spondyloarthropathies Braz J Med Biol Res 38 2005 801 805
63. C. Palazzi, I. Olivieri, E. D'Amico, and et al. Hepatitis C virus infection in psoriatic arthritis Arthritis Rheum 53 2005 223 225
64. A. Csepregi, G. Poor, and E. Nemesanszky Hepatitis C virus and rheumatoid arthritis: further pieces to the puzzle J Rheumatol 31 2004 1016 1017
65. F.C. Hsu, G. Starkebaum, E.J. Boyko, and et al. Prevalence of rheumatoid arthritis and hepatitis C in those age 60 and older in a US population based study J Rheumatol 30 2003 455 458
66. J.F. Maillefert, G. Muller, G. Falgarone, and et al. Prevalence of hepatitis C virus infection in patients with rheumatoid arthritis Ann Rheum Dis 61 2002 635 637
67. M. Ramos-Casals, J. Font, M. Garcia-Carrasco, and et al. Hepatitis C virus infection mimicking systemic lupus erythematosus: study of hepatitis C virus infection in a series of 134 Spanish patients with systemic lupus erythematosus Arthritis Rheum 43 2000 2801 2806
68. F.J. Munoz-Rodriguez, D. Tassies, J. Font, and et al. Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome J Hepatol 30 1999 770 773
69. T. Himoto, and T. Masaki Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection Clin Dev Immunol 2012 2012 871401
70. M. Bombardieri, C. Alessandri, G. Labbadia, and et al. Role of anti-cyclic citrullinated peptide antibodies in discriminating patients with rheumatoid arthritis from patients with chronic hepatitis C infection-associated polyarticular involvement Arthritis Res Ther 6 2004 R137 R141
71. T. Watanabe, and Y. Tanaka Reactivation of hepatitis viruses following immunomodulating systemic chemotherapy Hepatol Res 43 2013 113 121
72. M.Y. Mok, W.L. Ng, M.F. Yuen, and et al. Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis Clin Exp Rheumatol 18 2000 363 368
73. C. Giannitti, F. Bellisai, C. Ferri, and et al. Treatment strategies for a patient with rheumatoid arthritis and hepatitis C Expert Opin Pharmacother 10 2009 579 587
74. A.M. Brunasso, M. Puntoni, A. Gulia, and et al. Safety of anti-tumour necrosis factor agents in patients with chronic hepatitis C infection: a systematic review Rheumatol Oxf 50 2011 1700 1711
75. J.A. Singh, D.E. Furst, A. Bharat, and et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis Arthritis Care Res Hob 64 2012 625 639
76. L. Costa, F. Caso, M. Atteno, and et al. Long-term safety of anti-TNF-alpha in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients Clin Rheumatol 33 2014 273 276
77. S. De Vita, L. Quartuccio, M. Isola, and et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis Arthritis Rheum 64 2012 843 853
78. K.M. Lin, J.C. Lin, W.Y. Tseng, and et al. Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis J Microbiol Immunol Infect 46 2013 65 67
79. C. Dragonas, B. Ehrenstein, and M. Fleck Tocilizumab treatment in a patient suffering from rheumatoid arthritis and concomitant chronic hepatitis C infection Rheumatol Oxf 51 2012 1520 1521
80. T. Nagashima, A. Maruyama, Y. Kamata, and et al. Unchanged serum viral load and liver function during tocilizumab treatment in a patient with rheumatoid arthritis and hepatitis C virus infection Rheumatol Int 32 2012 2231 2232
81. C. Ferri, M. Sebastiani, A. Antonelli, and et al. Current treatment of hepatitis C-associated rheumatic diseases Arthritis Res Ther 14 2012 215
82. R.C. Axtell, and C. Raman Janus-like effects of type I interferon in autoimmune diseases Immunol Rev 248 2012 23 35
83. J.C. Hall, and A. Rosen Type I interferons: crucial participants in disease amplification in autoimmunity Nat Rev Rheumatol 6 2010 40 49
84. I. Kotter, V. Hamuryudan, Z.E. Ozturk, and et al. Interferon therapy in rheumatic diseases: state-of-the-art 2010 Curr Opin Rheumatol 22 2010 278 283
85. T. Okanoue, S. Sakamoto, Y. Itoh, and et al. Side effects of high-dose interferon therapy for chronic hepatitis C J Hepatol 25 1996 283 291
86. M. Biggioggero, L. Gabbriellini, and P.L. Meroni Type I interferon therapy and its role in autoimmunity Autoimmunity 43 2010 248 254
87. R. Rizvi, and M. Hojjati Interferon-alpha induced lupus in a patient with chronic hepatitis C virus J Clin Rheumatol 17 2011 152 153
88. M. Fritz, K. Vats, and R.K. Goyal Neonatal lupus and IUGR following alpha-interferon therapy during pregnancy J Perinatol 25 2005 552 554
89. G. Nesher, and R. Ruchlemer Alpha-interferon-induced arthritis: clinical presentation treatment, and prevention Semin Arthritis Rheum 27 1998 360 365
90. B. Cacopardo, F. Benanti, M.R. Pinzone, and et al. Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: a case report and review of the literature BMC Res Notes 6 2013 437
91. S. Alazemi, and M.A. Campos Interferon-induced sarcoidosis Int J Clin Pract 60 2006 201 211
92. L.M. Burdick, N. Somani, and A.K. Somani Type I IFNs and their role in the development of autoimmune diseases Expert Opin Drug Saf 8 2009 459 472
93. P. Piot, and T.C. Quinn Response to the AIDS pandemic-a global health model N Engl J Med 368 2013 2210 2218
94. W. Louthrenoo Rheumatic manifestations of human immunodeficiency virus infection Curr Opin Rheumatol 20 2008 92 99
95. W. Louthrenoo Musculoskeletal manifestations of HIV infection in Thailand: an analysis of 100 cases J Clin Rheumatol 3 1997 258 268
96. A. Azeroual, H. Harmouche, L. Benjilali, and et al. Rheumatoid arthritis associated to HIV infection Eur J Intern Med 19 2008 e34 e35
97. G.M. Mody, N. Patel, A. Budhoo, and et al. Concomitant systemic lupus erythematosus and HIV: case series and literature review Semin Arthritis Rheum 44 2014 186 194
98. R. Winchester, D.H. Bernstein, H.D. Fischer, and et al. The co-occurrence of Reiter's syndrome and acquired immunodeficiency Ann Intern Med 106 1987 19 26
99. M. Duvic, T.M. Johnson, R.P. Rapini, and et al. Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome Arch Dermatol 123 1987 1622 1632
100. W. Louthrenoo Successful treatment of severe Reiter's syndrome associated with human immunodeficiency virus infection with etretinate. Report of 2 cases J Rheumatol 20 1993 1243 1246
101. E. Disla, H.R. Rhim, A. Reddy, and et al. Improvement in CD4 lymphocyte count in HIV-Reiter's syndrome after treatment with sulfasalazine J Rheumatol 21 1994 662 664
102. G. Chiang, M. Sassaroli, M. Louie, and et al. Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine Clin Ther 18 1996 1080 1092
103. E.J. Cepeda, F.M. Williams, M.L. Ishimori, and et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease Ann Rheum Dis 67 2008 710 712
104. R. Evans, A. Gueret-Wardle, S. Edwards, and et al. ANCA-associated vasculitis and pauci-immune glomerulonephritis in HIV disease BMJ Case Rep 2014 Apr 1 2014
105. C. Gavegnano, M. Detorio, C. Montero, and et al. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro Antimicrob Agents Chemother 58 2014 1977 1986
106. L.H. Calabrese, E. Kirchner, and R. Shrestha Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease Semin Arthritis Rheum 35 2005 166 174
107. J. Marquez, C.S. Restrepo, L. Candia, and et al. Human immunodeficiency virus-associated rheumatic disorders in the HAART era J Rheumatol 31 2004 741 746
108. D. Basu, F.M. Williams, C.W. Ahn, and et al. Changing spectrum of the diffuse infiltrative lymphocytosis syndrome Arthritis Rheum 55 2006 466 472
109. A. Mastroianni Emergence of Sjogren's syndrome in AIDS patients during highly active antiretroviral therapy AIDS 18 2004 1349 1352
110. L. Iordache, O. Launay, O. Bouchaud, and et al. Autoimmune diseases in HIV-infected patients: 52 cases and literature review Autoimmun Rev 13 2014 850 857
111. J.J. Yang, M.S. Tsai, H.Y. Sun, and et al. Autoimmune diseases-related arthritis in HIV-infected patients in the era of highly active antiretroviral therapy J Microbiol Immunol Infect 48 2015 130 136
112. B.P. Yawn, and D. Gilden The global epidemiology of herpes zoster Neurology 81 2013 928 930
113. E.F. Chakravarty, K. Michaud, R. Katz, and et al. Increased incidence of herpes zoster among patients with systemic lupus erythematosus Lupus 22 2013 238 244
114. B.M. Veetil, E. Myasoedova, E.L. Matteson, and et al. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study Arthritis Care Res Hob 65 2013 854 861
115. E.F. Borba, A.C. Ribeiro, P. Martin, and et al. Incidence, risk factors, and outcome of Herpes zoster in systemic lupus erythematosus J Clin Rheumatol 16 2010 119 122
116. A.L. Smitten, H.K. Choi, M.C. Hochberg, and et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom Arthritis Rheum 57 2007 1431 1438
117. F. Wolfe, K. Michaud, and E.F. Chakravarty Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders Rheumatol Oxf 45 2006 1370 1375
118. P.K. Wung, J.T. Holbrook, G.S. Hoffman, and et al. Herpes zoster in immunocompromised patients: incidence, timing, and risk factors Am J Med 118 2005 1416
119. H.B. Park, K.C. Kim, J.H. Park, and et al. Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus J Rheumatol 31 2004 2151 2155
120. K.L. Winthrop, J.W. Baddley, L. Chen, and et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster JAMA 309 2013 887 895
121. J.B. Galloway, L.K. Mercer, A. Moseley, and et al. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register Ann Rheum Dis 72 2013 229 234
122. J. Zhang, F. Xie, E. Delzell, and et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases JAMA 308 2012 43 49
123. H. Che, C. Lukas, J. Morel, and et al. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis Jt Bone Spine 81 2014 215 221
124. N. Zhang, S. Wilkinson, M. Riaz, and et al. Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? A systematic literature review Clin Exp Rheumatol 30 2012 962 971
125. H. Yun, F. Xie, E. Delzell, and et al. Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease modifying therapy Arthritis Care Res Hob 67 2015 731 736
126. R.F. van Vollenhoven, P. Emery, C.O. Bingham 3rd, and et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients Ann Rheum Dis 72 2013 1496 1502
127. H. Nakajima, A. Takayama, T. Ito, and et al. Acute encephalomyelitis with multiple herpes viral reactivations during abatacept therapy BMJ Case Rep 2013 May 9 2013
128. K.L. Winthrop, H. Yamanaka, H. Valdez, and et al. Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis Arthritis Rheumatol 66 2014 2675 2684
129. K. Nagasawa, Y. Yamauchi, Y. Tada, and et al. High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis Ann Rheum Dis 49 1990 630 633
130. R. Harpaz, I.R. Ortega-Sanchez, and J.F. Seward Advisory committee on immunization practices centers for disease C, prevention. prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep 57 2008 1 30
131. A.H. Draborg, K. Duus, and G. Houen Epstein-Barr virus in systemic autoimmune diseases Clin Dev Immunol 2013 2013 535738
132. R. Rizzi, P. Curci, M. Delia, and et al. Spontaneous remission of "methotrexate-associated lymphoproliferative disorders" after discontinuation of immunosuppressive treatment for autoimmune disease. Review of the literature Med Oncol 26 2009 1 9
133. W.H. Feng, J.I. Cohen, S. Fischer, and et al. Reactivation of latent Epstein-Barr virus by methotrexate: a potential contributor to methotrexate-associated lymphomas J Natl Cancer Inst 96 2004 1691 1702
134. E. Baecklund, A. Iliadou, J. Askling, and et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis Arthritis Rheum 54 2006 692 701
135. J. Askling, C.M. Fored, E. Baecklund, and et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists Ann Rheum Dis 64 2005 1414 1420
136. M.A. Lopez-Olivo, J.H. Tayar, J.A. Martinez-Lopez, and et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis JAMA 308 2012 898 908
137. C. Miceli-Richard, N. Gestermann, C. Amiel, and et al. Effect of methotrexate and anti-TNF on Epstein-Barr virus T-cell response and viral load in patients with rheumatoid arthritis or spondylarthropathies Arthritis Res Ther 11 2009 R77
138. A. Komatsuda, Y. Okamoto, T. Hatakeyama, and et al. Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus Clin Rheumatol 27 2008 395 397
139. C. Soderberg-Naucler Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med 259 2006 219 246
140. Y. Takizawa, S. Inokuma, Y. Tanaka, and et al. Clinical characteristics of cytomegalovirus infection in rheumatic diseases: multicentre survey in a large patient population Rheumatol Oxf 47 2008 1373 1378
141. M. Yamashita, T. Ishii, N. Iwama, and et al. Incidence and clinical features of cytomegalovirus infection diagnosed by cytomegalovirus pp65 antigenemia assay during high dose corticosteroid therapy for collagen vascular diseases Clin Exp Rheumatol 24 2006 649 655
142. Y. Yoda, R. Hanaoka, H. Ide, and et al. Clinical evaluation of patients with inflammatory connective tissue diseases complicated by cytomegalovirus antigenemia Mod Rheumatol 16 2006 137 142
143. M. Ramos-Casals, M.J. Cuadrado, P. Alba, and et al. Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature Med Baltim 87 2008 311 318
144. J. Zhang, Y. Dou, Z. Zhong, and et al. Clinical characteristics and therapy exploration of active human cytomegalovirus infection in 105 lupus patients Lupus 23 2014 889 897
145. J. Torre-Cisneros, M. Del Castillo, J.J. Caston, and et al. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis Rheumatol Oxf 44 2005 1132 1135
146. S.Y. Kim, and D.H. Solomon Tumor necrosis factor blockade and the risk of viral infection Nat Rev Rheumatol 6 2010 165 174
147. H. Vallet, R. Houitte, A. Azria, and et al. Cytomegalovirus colitis and hypo-IgG after rituximab therapy for rheumatoid arthritis J Rheumatol 38 2011 965 966
148. A. Bellizzi, C. Nardis, E. Anzivino, and et al. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies J Neurovirol 18 2012 1 11
149. K.R. Carson, D. Focosi, E.O. Major, and et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project Lancet Oncol 10 2009 816 824
150. J. Bayliss, T. Karasoulos, and C.A. McLean Immunosuppression increases JC polyomavirus large T antigen DNA load in the brains of patients without progressive multifocal leukoencephalopathy J Infect Dis 207 2013 133 136
151. E.S. Molloy, and L.H. Calabrese Progressive multifocal leukoencephalopathy: a national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases Arthritis Rheum 60 2009 3761 3765
152. A. Bharat, F. Xie, J.W. Baddley, and et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases Arthritis Care Res Hob 64 2012 612 615
153. D.B. Clifford, B. Ances, C. Costello, and et al. Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis Arch Neurol 68 2011 1156 1164
154. E.V. Arkema, R.F. van Vollenhoven, J. Askling, and et al. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study Ann Rheum Dis 71 2012 1865 1867
155. L.H. Calabrese, E.S. Molloy, D. Huang, and et al. Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease Arthritis Rheum 56 2007 2116 2128
156. E. Palazzo, and S.A. Yahia Progressive multifocal leukoencephalopathy in autoimmune diseases Jt Bone Spine 79 2012 351 355
157. K. Kobayashi, Y. Okamoto, H. Inoue, and et al. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA) Intern Med 48 2009 1307 1309
158. M. Ray, J.R. Curtis, and J.W. Baddley A case report of progressive multifocal leucoencephalopathy (PML) associated with adalimumab Ann Rheum Dis 73 2014 1429 1430
159. E.J. Boren, G.S. Cheema, S.M. Naguwa, and et al. The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases J Autoimmun 30 2008 90 98
160. P.S. Moore The emergence of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) N Engl J Med 343 2000 1411 1413
161. W. Louthrenoo, N. Kasitanon, P. Mahanuphab, and et al. Kaposi's sarcoma in rheumatic diseases Semin Arthritis Rheum 32 2003 326 333
162. V. Amadu, R. Satta, M.A. Montesu, and et al. Kaposi's sarcoma associated with treatment with adalimumab Dermatol Ther 25 2012 619 620
163. F. Ursini, S. Naty, V. Mazzei, and et al. Kaposi's sarcoma in a psoriatic arthritis patient treated with infliximab Int Immunopharmacol 10 2010 827 828
164. F. Ingegnoli, A. Tourlaki, and R. Gualtierotti Tocilizumab monotherapy in a patient with rheumatoid arthritis and iatrogenic Kaposi sarcoma Clin Drug Investig 34 2014 159 161
165. A. Handisurya, C. Schellenbacher, and R. Kirnbauer Diseases caused by human papillomaviruses (HPV) J Dtsch Dermatol Ges 7 2009 453 466
166. D. Wiley, and E. Masongsong Human papillomavirus: the burden of infection Obstet Gynecol Surv 61 2006 S3 S14
167. M.H. Einstein, J.T. Schiller, R.P. Viscidi, and et al. Clinician's guide to human papillomavirus immunology: knowns and unknowns Lancet Infect Dis 9 2009 347 356
168. W. Rojo-Contreras, E.M. Olivas-Flores, J.I. Gamez-Nava, and et al. Cervical human papillomavirus infection in Mexican women with systemic lupus erythematosus or rheumatoid arthritis Lupus 21 2012 365 372
169. E. Zard, L. Arnaud, A. Mathian, and et al. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: a meta-analysis of the literature Autoimmun Rev 13 2014 730 735
170. L.S. Tam, P.K. Chan, S.C. Ho, and et al. Natural history of cervical papilloma virus infection in systemic lupus erythematosus - a prospective cohort study J Rheumatol 37 2010 330 340
171. I.U. Santana, N. Gomes Ado, L.D. Lyrio, and et al. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review Clin Rheumatol 30 2011 665 672
172. J.M. Guthridge, A. Cogman, J.T. Merrill, and et al. Herpes zoster vaccination in SLE: a pilot study of immunogenicity J Rheumatol 40 2013 1875 1880
173. Y. Zafrir, N. Agmon-Levin, Z. Paz, and et al. Autoimmunity following hepatitis B vaccine as part of the spectrum of 'Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants' (ASIA): analysis of 93 cases Lupus 21 2012 146 152
174. M. Gatto, N. Agmon-Levin, A. Soriano, and et al. Human papillomavirus vaccine and systemic lupus erythematosus Clin Rheumatol 32 2013 1301 1307
175. N. Agmon-Levin, G.R. Hughes, and Y. Shoenfeld The spectrum of ASIA: 'autoimmune (auto-inflammatory) syndrome induced by adjuvants' Lupus 21 2012 118 120